below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 21 Sept. 2001

By: Daniel Altman

Daniel E. Altman
Registration No. 34,115
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

H:\DOCS\JAH\JAH-4949.DOC
091801

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

On page 1, line 2, after the Title of the Invention, please insert:

--This is the U.S. National Phase under 35 U.S.C.§371 of International Application PCT/JP00/01801, filed March 24, 2000, which claims priority of Japanese Applications JP 1999-84395, filed March 26, 1999, JP 1999-123633, filed April 30, 1999, and JP 1999-173731, filed June 21, 1999 (all of which are herein incorporated by reference).--.

On page 2, please replace the first paragraph (starting on line 4 and ending on line 9) as follows:

--An object of the present invention is to provide a food composition, a pharmaceutical composition and an external preparation for skin, which comprises as an active ingredient a compound **[having excellent]**surprising effective at suppressing type I allergy **[suppression effect]**and its symptoms, and thus **[have]**having an excellent preventative or therapeutic effect on type I allergy **[preventive or therapeutic effect]**.--.

On page 2, please replace the third paragraph (starting on line 15 and ending on line 19) as follows:

--The inventors discovered, during atopic dermatitis screening, that astragalin **[has an action]**is capable of suppressing atopic dermatitis and **[an action of suppressing]**can also suppress a rise in serum IgE level, and also discovered that astragalin suppresses the symptoms of pollinosis.--.

On page 4, please replace the Figure legends (starting on line 7 and ending on line 11) as follows:

-- Fig. 1 shows the suppressive effect of kaempferol-3-glucoside (astragalin) **[of suppressing]**on passive cutaneous anaphylaxis (PCA) in mice (Experimental Example 1);

Fig. 2 shows the suppressive effect of astragalin **[of suppressing]**on histamine release (Experimental Example 2);--.

On page 5, please replace the third paragraph (starting on line 13 and ending on line 16) as follows:

--Astragalin **[has an action]**is capable of suppressing a rise in serum IgE level, and hence the food composition of the present invention can also be used for suppressing a rise in serum IgE level.--.

On page 14, please replace the first paragraph (starting on line 3 and ending on line 6) as follows:

--Astragalin **[has an action]**is capable of suppressing a rise in serum IgE level, and hence the pharmaceutical composition of the present invention can also be used for suppressing a rise in serum IgE level.--.

On page 17, please replace the second paragraph (starting on line 9 and ending on line 11) as follows:

--The external preparation for skin of the present invention **[has an action]**is capable of improving rough skin conditions, and hence can be used for improving rough skin conditions.--.

On page 30, please replace the first paragraph (starting on line 1 and ending on line 6) with the following:

--Two of the volunteers had a rough skin condition **[at the time of starting to drink]**before treatment in the form of administration of the astragalin solution by drinking, but the condition improved while drinking the astragalin solution. Rough skin conditions can also be expected to be improved upon applying astragalin to the skin in the form of a cosmetic.--.

On page 33, please cancel the word "CLAIMS" and substitute in its place --WHAT IS CLAIMED IS:--.

**IN THE CLAIMS**

**Please cancel Claims 2-6.**

**Please replace the remaining claims with the following claims:**

1. **(Amended)** A composition for preventing or treating type I allergy and diseases associated with type I allergy, comprising kaempferol-3-glucoside (astragalin) **[as an active ingredient]**in an amount effective to prevent or treat type I allergy and the diseases associated with type I allergy.

7. **(Amended)** A method for preventing or treating type I allergy and diseases associated with type I allergy in a mammal,**[by ingesting or]**comprising:

administering to said mammal an effective amount of kaempferol-3-glucoside to prevent or treat type I allergy and the diseases associated with type I allergy.

8. **(Amended)** The method according to claim 7, wherein the diseases associated with type I allergy are atopic diseases.

9. **(Amended)** The method according to claim **[7]**8, wherein the diseases associated with type I allergy **[is pollinosis]**are selected from the group consisting of: atopic dermatitis, brochial asthma, allergic rhinitis, allergic contact dermatitis, pollinosis, and urticaria.

**Please add the following claims:**

10. The method according to claim 7 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

11. The method of claim 10 wherein the effective amount is from about 0.05 to about 1.5 mg per day per kg of body weight.

12. The method of claim 7 wherein the administration is selected from the group consisting of: orally, intravenously, topically, intramuscularly, intracutaneously, subcutaneously, intraperitoneally, and by aerosolization.

13. The method of claim 12, wherein the administration is orally, admixed with a food product.

14. The method of claim 13, wherein the food product is selected from the group consisting of: juice, soft drinks, teas, powdered soups, jelly, cookies, biscuits, cereal, crackers, candy, breads, noodles, fish paste, chewing gum, ice cream, and chocolate.

15. The method of claim 7 wherein the administration is between one and 4 doses per day.

16. The composition according to claim 1 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

17. The composition of claim 1 wherein the effective amount is from about 0.05 to about 1.5 mg per day per kg of body weight.

18. A pharmaceutical composition comprising the composition of claim 1 with a pharmaceutically acceptable carrier, diluent, or excipient.

19. The pharmaceutical composition of claim 18, wherein said carrier, diluent, or excipient is selected from the group consisting of: powders, lotions, ointments, binders, surfactants, moisturizers, fillers, extenders, wetting agents and food products.

20. The pharmaceutical composition of claim 18 further comprising: antiseptics, colerants, preservatives, antioxidants, aromatics, and food products.

21. The composition of claim 1 wherein said kaempferol-3-glucoside is extracted from plants or chemically synthesized.

22. The composition of claim 21, wherein said plants are selected from the group consisting of: persimmon, amachazuru, gymnema, guava, kuko, striped bamboo, jasmine, sugina, dokudami, loquat, sen-cha, and tien-cha.

23. A method for the reduction of serum IgE in a mammal, comprising:

administering an amount of kaempferol-3-glucoside to said mammal sufficient to reduce serum IgE.